The Hungarian Vaccines Market Is Projected to Grow at Cagr of 4.45% to Reach a Revenue of $82.75m by 2023


According to the new market research report by IndustryARC titled “Hungarian Vaccines Market: By Type, By Technology, By Disease Indication, By End User, and By Geography Analysis – Forecast (2018 – 2023),” the market is driven by the new technological advancements and collaboration strategies adopted by key players.

The Inactivated Vaccines segment holds the major share in Hungarian Vaccines Market

The Inactivated Vaccines segment dominated the market with a large market share. Researchers and market players invest in R&D to develop safe and effective vaccines and introduce new inactivated vaccines after clinical studies have been completed, thus boosting the growth of the inactivated vaccines market. The increasing prevalence of various viral and bacterial diseases has increased the demand for inactivated vaccines, which in turn is fuelling the growth of the market. The Hungary Inactivated Vaccines Market is projected to grow at a CAGR of 5.06%.

View Full Table of Contents of Hungarian Vaccines Market:

Selected/Sample Analysis done in full report

By Disease, the Influenza segment has witnessed a large growth due to the fact that it is the most common disease that can occur to any age group of people. Influenza resolves on its own for most people. But sometimes influenza and its complications can be deadly for young children under the age of 5, particularly children under 2 years of age and adults older than 65 years. In Hungary, those aged ≥65 years are recommended for vaccination for influenza.

By End User, the Pediatrics segment is on growth because of increased incidence of infant diseases such as chicken pox, typhoid, cholera, measles, and hepatitis, leading to high demand for immunization, which has a positive effect on the vaccines market.

Excerpts on Market Growth Factors

Based on diseases, the Influenza segment is expected to hold a major share of the market.
GlaxoSmithKline is expanding vaccine production in Hungary and has invested HUF 18 billion into its Hungarian Vaccine Unit.

The rising company initiatives to enhance the R&D in vaccines and the growing government support for vaccine development are projected to accelerate the growth of the Hungarian vaccines market in the next few years.

Key players of the Hungarian Vaccines Market

Pfizer Inc., a New York-based company which operates in more than 60 countries offers various types of product such as Prevnar 13/Prevenar 13, Nimenrix, Trumenba and Others. The major competitors in this market are GlaxoSmithKline, Merck and Co, Sanofi Pasteur and many more.

Related Reports:

1. Veterinary Vaccines Market

2. Medical Robotics Market

What can you expect from the report?
The Hungarian Vaccines Market is Prepared with the Main Agenda to Cover the following 20 points:
1. Hungarian Vaccines Market Size by Product Categories & Application
2. Hungarian Vaccines Market trends & Relevant Market Data
3. Manufacturer Landscape
4. Distributor Landscape
5. Pricing Analysis
6. Top 10 End-user Analysis
7. Product Benchmarking
8. Product Developments
9. Mergers & Acquisition Analysis
10. Patent Analysis
11. Hungarian Vaccines Market Demand Analysis (Revenue & Volume)
12. Country-level Analysis
13. Competitor Analysis
14. Hungarian Vaccines Market Shares Analysis
15. Value Chain Analysis
16. Supply Chain Analysis
17. Hungarian Vaccines Market Strategic Analysis
18. Hungarian Vaccines Market Current & Future Market Landscape Analysis
19. Opportunity Analysis
20. Hungarian Vaccines Market Revenue and Volume Analysis

Media Contact:
Mr. Venkat Reddy
Sales Manager
Contact Sales: +1-614-588-8538 (Ext-101)

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.


Go to website